The second patient with a PR was a 68-year-old woman with ovarian cancer that stained 5% for PD-L1, who was previously treated with surgery and four previous regimens, which, in total, consisted of carboplatin, paclitaxel, gemcitabine, bevacizumab, docetaxel and an investigational agent (Fig. 3c). Here, CD274 is linked to ovarian cancer.